Well, here we are again, looking back at another massive round of biotech IPOs priced just last week, as the beat goes on and on and… My trusty, hand-held calculator… Read more »
The News: Last week the Nasdaq Biotech Index swooned 4% on Wednesday (July 27, 2018), only to rebound and halve that downdraft by Friday’s close (July 29, 2018). But despite… Read more »
In recent years, biotech IPOs came one, or maybe two, most weeks. But in 2018, things are very different. Last week, a mind boggling eight were priced, simultaneously testing investors’ appetite… Read more »
It’s been said that biotechs are among the riskiest of initial public offerings due to the dualistic nature of their meds: they either succeed or they flop. There’s usually no… Read more »
The News: US Food and Drug Administration chief Scott Gottlieb on Thursday (May 3, 2018) questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law,… Read more »
Steve’s Take: After a perfectly miserable 2016, IPO issuers have been praying for a New England Patriots-style comeback. Bob Pisani at CNN says there are reasons to be optimistic. Leading… Read more »
